CN113373127A - Taq DNA polymerase mutant and application thereof - Google Patents
Taq DNA polymerase mutant and application thereof Download PDFInfo
- Publication number
- CN113373127A CN113373127A CN202110640339.8A CN202110640339A CN113373127A CN 113373127 A CN113373127 A CN 113373127A CN 202110640339 A CN202110640339 A CN 202110640339A CN 113373127 A CN113373127 A CN 113373127A
- Authority
- CN
- China
- Prior art keywords
- leu
- dna polymerase
- taq dna
- ala
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
Abstract
The invention discloses a Taq DNA polymerase mutant and application thereof. The invention provides a Taq DNA polymerase single-site mutant with improved thermostability, which is obtained by carrying out single-site mutation in G79E, G80A, D177E, A180V, E189P, S357A, A472E or G504K on an amino acid sequence shown in SEQ ID No. 1. The invention provides a Taq DNA polymerase multi-site mutant with further improved thermal stability on the basis of single-site mutation. qPCR thermal stability detection shows that the single-site or multi-site mutant of the Taq DNA polymerase provided by the invention has obviously improved enzyme activity compared with wild type Taq DNA polymerase, and the thermal stability is obviously superior to that of the wild type Taq DNA polymerase. The invention also provides the application of the mutant as Taq DNA polymerase in gene amplification.
Description
The present application is a divisional application of the parent application entitled "Taq DNA polymerase mutant and use thereof" having application number "202110342666.5" and having application date "3/30/2021".
Technical Field
The invention relates to a polymerase mutant, in particular to a Taq DNA polymerase mutant with improved thermal stability and application thereof, belonging to the field of Taq DNA polymerase mutants.
Background
Taq DNA polymerase was the first found thermostable DNA polymerase, originally extracted from a strain of Thermobacter aquaticus (thermus aquaticus) isolated from hot springs by Saiki et al. The enzyme can resist high temperature, Taq DNA polymerase can be used for DNA sequence determination in molecular cloning, and Polymerase Chain Reaction (PCR) can be used for in vitro amplification of specific fragments of DNA. During PCR, since Taq DNA polymerase is not inactivated during the denaturation step (about 94 ℃) and can directly enter the second cycle, it is not necessary to add new enzyme every cycle, which makes Taq DNA polymerase a unique enzyme in PCR reaction.
However, if the number of cycles of Taq DNA polymerase is too large or the amplification temperature is high during PCR amplification, the enzyme activity is reduced, which leads to inaccurate amplification results, and thus, it is necessary to improve the thermostability of Taq DNA polymerase.
Disclosure of Invention
One of the objects of the present invention would be to provide a Taq DNA polymerase single site mutant with improved thermal stability;
the second object of the present invention is to provide a Taq DNA polymerase multi-site mutant with improved thermostability;
the third object of the present invention is to provide a method for preparing the Taq DNA polymerase single-site mutant or multi-site mutant;
the fourth purpose of the invention is to apply the Taq DNA polymerase single site mutant or multi-site mutant to polymerization amplification.
In order to achieve the purpose, the technical scheme adopted by the invention comprises the following steps:
as a specific embodiment of the present invention, the present invention provides a Taq DNA polymerase single-site mutant with improved thermostability, which is a mutant obtained by subjecting the amino acid sequence shown in SEQ ID No.1 to any one of the amino acid single-site mutations of G79E, G80A, D177E, A180V, E189P, S357A, A472E or G504K; preferably, the mutant is obtained by subjecting the amino acid sequence shown in SEQ ID No.1 to single-site mutation of any one of the amino acid sequences G79E, A180V or G504K; more preferably, the amino acid sequence shown in SEQ ID No.1 is subjected to single-site mutation of any one of A180V or G504K to obtain a mutant.
The single-site mutant 'G79E' of the invention refers to that the 79 th amino acid of Taq DNA polymerase with the amino acid sequence shown in SEQ ID NO.1 is mutated from glycine (G) to glutamic acid (E); the expression of the remaining single-site mutations of the invention is analogized.
As a specific embodiment of the present invention, the present invention provides a Taq DNA polymerase multi-site mutant with improved thermostability, the multi-site mutant being selected from any one of the following (a) to (d):
(a) a mutant (A180V/G504K) obtained by simultaneously carrying out mutation on two sites of A180V and G504K on the amino acid sequence shown in EQ ID No. 1;
(b) a mutant (G79E/E189P) obtained by simultaneously carrying out mutation on the amino acid sequence shown in EQ ID No.1 at two sites of G79E and E189P;
(c) a mutant obtained by simultaneously carrying out mutation on four sites of A180V, G504K, G79E and E189P on the amino acid sequence shown in EQ ID No.1 (A180V/G504K/G79E/E189P);
(d) a mutant obtained by carrying out mutation on six sites of A180V, G504K, G79E, E189P, D177E and G80A on the amino acid sequence shown in EQ ID No.1 at the same time (A180V/G504K/G79E/E189P/D177E/G80A).
The multi-site mutant "A180V/G504K" of the present invention means that alanine (A) at position 180 of Taq DNA polymerase having the amino acid sequence shown in SEQ ID NO.1 is mutated to valine (V) and glycine (G) at position 504 is mutated to lysine (K); the expression of the multi-site mutations of other said amino acids of the invention is analogized.
The encoding gene of the Taq DNA polymerase single-site mutant or multi-site mutant also belongs to the protection scope of the invention.
The invention also discloses a recombinant expression vector or a recombinant host cell containing the encoding gene of the Taq DNA polymerase single-site mutant or multi-site mutant; wherein, the recombinant expression vector can be a recombinant prokaryotic expression vector or a recombinant eukaryotic vector.
The present invention further provides a method for preparing any one of the Taq DNA polymerase mutants, comprising:
(1) connecting the encoding gene of the Taq DNA polymerase mutant with an expression regulation element in an operable manner to construct a recombinant expression vector;
(2) transforming the recombinant expression vector into a host cell, culturing the host cell, inducing and expressing the recombinant protein, and purifying to obtain the recombinant protein.
The invention also discloses the application of the Taq DNA polymerase mutant as DNA polymerase in gene amplification.
Detailed description of the invention
Design, screening and enzymology performance detection of TaqDNA polymerase single-site mutant
In order to further improve the thermal stability of the Taq enzyme, 23 single-point mutations of the Taq enzyme are obtained by methods such as gene consensus and AI model co-design, after the 23 single-point mutants are successfully constructed, the wild type and the mutant of the Taq enzyme are respectively subjected to heat treatment under the following conditions: 30S at 95 ℃; 30S at 60 ℃; 60S at 72 ℃, and different numbers of heat treatment cycles are set. The control group was prepared without heat treatment. Then carrying out normal PCR reaction at 95 ℃ for 5 min; 30S at 95 ℃, 30S at 60 ℃ and 60S at 72 ℃; 10min at 72 ℃. In order to compare the mutants more accurately by the gel electrophoresis of nucleic acids, the PCR reaction was set to 30 cycles in total. Previous experiments have found that the first 11 single-point mutants (H28Y, A61Y, G79E, A97P, A109P, D177E, A180P, T186V, D237E, A472E and G504K) are soaked for 30 cycles and repeated for three times, and the results show that the single-point mutations G79E, D177E, A180P, A472E and G504K have lighter bands than the wild type. However, since the number of heat treatment cycles is too large, the effect is not obvious, and the parallelism is poor, the five single-point mutations are re-tested. As shown in fig. 2, a180P activity was lost after 10 cycles of heat treatment, thus discarding this single point mutant. Finally, G79E, D177E, a472E and G504K were selected for the design of subsequent multiple mutations.
After the last 12 single-point mutants (D60K, G80A, A155V, A180V, E189P, L224V, L233K, H235F, M236L, D244E, A293P and S357A) are respectively subjected to heat treatment for different numbers of cycles, and normal PCR reaction is carried out, the result shows that the single-point mutants G80A, A180V, E189P and S357A have brighter bands than the wild type, which indicates that the thermal stability is better than that of the wild type, so that the four single-point mutations are selected for designing the subsequent multiple-point mutation.
Design, screening and enzymatic performance detection of TaqDNA polymerase multi-site mutant
Designing multi-point mutation according to the result of single-point mutation; after the thermal stability test is carried out on the Taq enzyme multi-point mutants, TD2(A180V/G504K), TD3(G79E/E189P), TD5(A180V/G504K/G79E/E189P) and TD6(A180V/G504K/G79E/E189P/D177E/G80A) are subjected to heat treatment, the bands are brighter than the wild type, and the thermal stability is higher than that of the wild type. Therefore, the present invention selects these four multi-point mutants for qPCR thermostability testing. The results show that the enzyme activities of TD2, TD5 and TD6 are improved to different degrees compared with wild type enzyme activities, wherein the enzyme activities of TD2 and TD6 are improved by more than two times, and in addition, after 10-cycle and 20-cycle heat treatment, the residual enzyme activity of TD2 is obviously higher than that of the wild type enzyme. Although the enzyme activity of TD3 is slightly lower than that of the wild type, after 20 cycles of heat treatment, the residual enzyme activity of TD3 is higher than that of the wild type, which indicates that the thermal stability is better than that of the wild type.
Definitions of terms to which the invention relates
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described.
The term "polynucleotide" or "nucleotide" means deoxyribonucleotides, deoxyribonucleosides, ribonucleosides, or ribonucleotides and polymers thereof in either single-or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have binding properties similar to the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specifically limited, the term also means oligonucleotide analogs, which include PNAs (peptide nucleic acids), DNA analogs used in antisense technology (phosphorothioates, phosphoramidates, and the like). Unless otherwise specified, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (including, but not limited to, degenerate codon substitutions) and complementary sequences as well as the sequence explicitly specified. In particular, degenerate codon substitutions may be achieved by generating sequences in which the 3 rd position of one or more selected (or all) codons is substituted with mixed base and/or deoxyinosine residues (Batzer et al, Nucleic Acid Res.19:5081 (1991); Ohtsuka et al, J.biol.chem.260: 2605-S2608 (1985); and Cassol et al (1992); Rossolini et al, Mol cell. probes 8:91-98 (1994)).
The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to mean a polymer of amino acid residues. That is, the description for a polypeptide applies equally to the description of a peptide and to the description of a protein, and vice versa. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues are a non-naturally encoded amino acid. As used herein, the term encompasses amino acid chains of any length, including full-length proteins (i.e., antigens), in which the amino acid residues are linked via covalent peptide bonds.
The terms "mutation" and "mutant" have their usual meanings herein, and refer to a genetic, naturally occurring or introduced change in a nucleic acid or polypeptide sequence, which has the same meaning as is commonly known to those of skill in the art.
The term "recombinant host cell strain" or "host cell" means a cell comprising a polynucleotide of the present invention, regardless of the method used for insertion to produce the recombinant host cell, e.g., direct uptake, transduction, f-pairing, or other methods known in the art. The exogenous polynucleotide may remain as a non-integrating vector, such as a plasmid, or may integrate into the host genome. The host cell may be a prokaryotic cell or a eukaryotic cell.
The term "operably linked" refers to a functional linkage between two or more elements that may be operably linked and may or may not be contiguous.
The term "transformation" refers to the genetic transformation of a polynucleotide or polypeptide into a host cell in such a manner that the encoding gene is introduced into the interior of the host cell.
The term "expression": transcription and/or translation of an endogenous gene or transgene in a host cell.
The term "coding gene": a nucleic acid sequence transcribed into RNA.
Drawings
FIG. 1 is a diagram showing the results of nucleic acid electrophoresis in the detection of thermal stability of a single-point mutant of Taq enzyme (No. 1-11);
FIG. 2 is a diagram showing the result of nucleic acid electrophoresis in the detection of the thermal stability of single-point mutants of Taq enzyme;
FIG. 3 is a diagram showing the results of nucleic acid electrophoresis in the detection of thermal stability of single-point mutants of Taq enzyme (Nos. 12-23);
FIG. 4 is a diagram of the result of nucleic acid electrophoresis in the detection of the thermal stability of the Taq enzyme multi-point mutant.
Detailed Description
The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. It is to be understood that the described embodiments are exemplary only and are not limiting upon the scope of the invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be within the scope of the invention.
Test example 1 design, screening and enzymatic Performance test of TaqDNA polymerase Single-site mutants
In order to further improve the thermostability of Taq enzyme, 23 single-point mutations of Taq enzyme were obtained in total by methods such as gene consensus and AI model co-design, as shown in table 1 below.
TABLE 1 Taq enzyme Single Point mutation site
After the 23 single-point mutants are successfully constructed, respectively carrying out heat treatment on the Taq enzyme wild type and the mutant, wherein the heat treatment conditions are as follows: 30S at 95 ℃; 30S at 60 ℃; 60S at 72 ℃, and different numbers of heat treatment cycles are set. The control group was prepared without heat treatment. Then carrying out normal PCR reaction at 95 ℃ for 5 min; 30S at 95 ℃, 30S at 60 ℃ and 60S at 72 ℃; 10min at 72 ℃. In order to compare the mutants more accurately by the gel electrophoresis of nucleic acids, the PCR reaction was set to 30 cycles in total.
Previous experiments revealed that the first 11 single-point mutants (H28Y, a61Y, G79E, a97P, a109P, D177E, a180P, T186V, D237E, a472E, G504K) were soaked for 30 cycles, which were repeated three times, and the results showed that the bands of the single-point mutations G79E, D177E, a180P, a472E and G504K were slightly brighter than the wild type (fig. 1). However, since the number of heat treatment cycles was too large, the effect was not significant, and the parallelism was poor, these five single point mutations were re-tested. As shown in fig. 2, a180P activity was lost after 10 cycles of heat treatment, thus discarding this single point mutant. Finally, G79E, D177E, a472E and G504K were selected for the design of subsequent multiple mutations.
After the last 12 single-point mutants (D60K, G80A, a155V, a180V, E189P, L224V, L233K, H235F, M236L, D244E, a293P and S357A) were subjected to heat treatment for different numbers of cycles respectively and subjected to normal PCR reaction, the results showed that the bands of the single-point mutants G80A, a180V, E189P and S357A were brighter than the wild type (fig. 3), indicating that the thermostability was better than the wild type, and therefore, the four single-point mutations were selected for subsequent multi-point mutation design.
Test example 2 design, screening and enzymatic Performance testing of TaqDNA polymerase Multi-site mutants
Based on the single point mutation results of test example 1, a multi-point mutation was designed, and the designed multi-point mutation sites are shown in Table 2.
TABLE 2 Taq enzyme multiple site mutations
The results of the thermal stability test showed that the Taq enzyme multipoint mutants TD2, TD3, TD5 and TD6 were brighter than the wild type after heat treatment (FIG. 4), indicating that the thermal stability was higher than the wild type.
Therefore, the present assay selects these four multi-point mutants for qPCR thermostability testing. The thermal stability detection results are shown in table 3, the enzyme activities of TD2, TD5 and TD6 are improved to different degrees compared with the wild type enzyme, wherein the enzyme activities of TD2 and TD6 are improved by more than two times, and in addition, after 10 cycles and 20 cycles of heat treatment, the residual enzyme activity of TD2 is significantly higher than that of the wild type enzyme. Although the enzyme activity of TD3 is slightly lower than that of the wild type, after 20 cycles of heat treatment, the residual enzyme activity of TD3 is higher than that of the wild type, which indicates that the thermal stability is better than that of the wild type.
TABLE 3 Taq enzyme multiple point mutant thermostability assay qPCR results
SEQUENCE LISTING
<110> institute of biotechnology of Chinese academy of agricultural sciences
<120> Taq DNA polymerase mutant and application thereof
<130> BJ-2002-210210F
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 832
<212> PRT
<213> thermus aquaticus
<400> 1
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Ala Leu His Pro Glu Gly
145 150 155 160
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320
Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro
325 330 335
Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu
340 345 350
Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro
355 360 365
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn
370 375 380
Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu
385 390 395 400
Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu
405 410 415
Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu
420 425 430
Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly
435 440 445
Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala
450 455 460
Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His
465 470 475 480
Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp
485 490 495
Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg
500 505 510
Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile
515 520 525
Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540
Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu
545 550 555 560
His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser
565 570 575
Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln
580 585 590
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly
610 615 620
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr
625 630 635 640
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
660 665 670
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu
675 680 685
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg
690 695 700
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val
705 710 715 720
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg
725 730 735
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro
740 745 750
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu
755 760 765
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala
785 790 795 800
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro
805 810 815
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
Claims (7)
1. A Taq DNA polymerase mutant with improved thermostability, which is characterized in that the mutant is obtained by carrying out G79E amino acid single site mutation on an amino acid sequence shown as SEQ ID No. 1.
2. A Taq DNA polymerase mutant with improved thermostability, which is obtained by simultaneously carrying out mutation at two sites of G79E and E189P on an amino acid sequence shown in EQ ID No. 1.
3. A gene encoding the Taq DNA polymerase mutant according to claim 1 or 2.
4. A recombinant expression vector comprising the gene of claim 3.
5. A recombinant host cell comprising the recombinant expression vector of claim 4.
6. A method for preparing the Taq DNA polymerase mutant according to claim 1 or 2, comprising the steps of:
(1) connecting the encoding gene of the Taq DNA polymerase mutant with an expression regulation element in an operable manner to construct a recombinant expression vector;
(2) transforming the recombinant expression vector into a host cell, culturing the host cell, inducing and expressing the recombinant protein, and purifying to obtain the recombinant protein.
7. The use of the Taq DNA polymerase mutant of claim 1 or 2 as Taq DNA polymerase in gene amplification.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110640339.8A CN113373127B (en) | 2021-03-30 | 2021-03-30 | Taq DNA polymerase mutant and application thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110640339.8A CN113373127B (en) | 2021-03-30 | 2021-03-30 | Taq DNA polymerase mutant and application thereof |
CN202110342666.5A CN112725301B (en) | 2021-03-30 | 2021-03-30 | Taq DNA polymerase mutant and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110342666.5A Division CN112725301B (en) | 2021-03-30 | 2021-03-30 | Taq DNA polymerase mutant and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113373127A true CN113373127A (en) | 2021-09-10 |
CN113373127B CN113373127B (en) | 2022-10-04 |
Family
ID=75596150
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110342666.5A Active CN112725301B (en) | 2021-03-30 | 2021-03-30 | Taq DNA polymerase mutant and application thereof |
CN202110640339.8A Active CN113373127B (en) | 2021-03-30 | 2021-03-30 | Taq DNA polymerase mutant and application thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110342666.5A Active CN112725301B (en) | 2021-03-30 | 2021-03-30 | Taq DNA polymerase mutant and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN112725301B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116200363A (en) * | 2021-11-30 | 2023-06-02 | 广州达安基因股份有限公司 | Taq enzyme mutant, preparation method and application thereof |
CN114774384A (en) * | 2022-04-26 | 2022-07-22 | 浙江大学杭州国际科创中心 | Taq DNA polymerase mutant and screening method thereof |
CN115261351B (en) * | 2022-06-08 | 2024-03-29 | 厦门通灵生物医药科技有限公司 | Reverse transcription-polymerization bifunctional enzyme and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111484987A (en) * | 2019-01-29 | 2020-08-04 | 中山大学达安基因股份有限公司 | Heat-resistant DNA polymerase mutant with high amplification activity |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9005895B2 (en) * | 2010-06-21 | 2015-04-14 | Life Technologies Corporation | Compositions, methods and kits for nucleic acid synthesis and amplification |
US9758773B2 (en) * | 2014-02-14 | 2017-09-12 | Agilent Technologies, Inc. | Thermostable type-A DNA polymerase mutant with increased resistance to inhibitors in blood |
EP3440221A1 (en) * | 2016-04-06 | 2019-02-13 | Life Technologies Corporation | Compositions, methods, and kits for synthesis and detection of nucleic acids |
CN109486919B (en) * | 2018-11-26 | 2019-11-01 | 南京诺唯赞生物科技有限公司 | A kind of PCR amplification reagent and its application |
CN109402082A (en) * | 2018-11-26 | 2019-03-01 | 南京诺唯赞生物科技有限公司 | A kind of Taq DNA polymerase mutant body and its application |
CN110684752B (en) * | 2019-10-08 | 2020-09-29 | 南京诺唯赞生物科技股份有限公司 | Mutant Taq DNA polymerase with improved tolerance as well as preparation method and application thereof |
CN110747183B (en) * | 2019-10-29 | 2020-10-23 | 南京诺唯赞生物科技股份有限公司 | Taq DNA polymerase mutant and application thereof |
CN111073871B (en) * | 2019-12-17 | 2021-02-26 | 中国科学院苏州生物医学工程技术研究所 | DNA polymerase mutant with improved thermal stability as well as construction method and application thereof |
CN112574971A (en) * | 2020-12-29 | 2021-03-30 | 益善生物技术股份有限公司 | Taq DNA polymerase mutant, PCR reaction reagent and kit |
-
2021
- 2021-03-30 CN CN202110342666.5A patent/CN112725301B/en active Active
- 2021-03-30 CN CN202110640339.8A patent/CN113373127B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111484987A (en) * | 2019-01-29 | 2020-08-04 | 中山大学达安基因股份有限公司 | Heat-resistant DNA polymerase mutant with high amplification activity |
Non-Patent Citations (3)
Title |
---|
KEE等: "Improved thermostability and PCR efficiency of Thermococcus celericrescens DNA polymerase via site-directed mutagenesis", 《JOURNAL OF BIOTECHNOLOGY》 * |
SHERINE等: "Modulation of the W748S mutation in DNA polymerase γ by the E1143G polymorphism in mitochondrial disorders", 《HUM MOL GENET》 * |
梁雪莲等: "耐热DNA聚合酶基因双元载体的初步构建", 《生物技术通报》 * |
Also Published As
Publication number | Publication date |
---|---|
CN113373127B (en) | 2022-10-04 |
CN112725301A (en) | 2021-04-30 |
CN112725301B (en) | 2021-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112725301B (en) | Taq DNA polymerase mutant and application thereof | |
AU2018310134B2 (en) | Atp phosphoribosyltransferase variant and method for producing l-histidine using the same | |
JP5308027B2 (en) | Mutant PCNA | |
Eriani et al. | Cysteinyl-tRNA synthetase: determination of the last E. coli aminoacyl-tRNA synthetase primary structure | |
US10883091B2 (en) | DNA polymerase variant and application thereof | |
CS324291A3 (en) | Increase in production of thermus aquaticus dna polymerase in escherichia coli | |
CN112585264A (en) | Recombinant KOD polymerase | |
AU2005245966A1 (en) | Thermostable Y-family polymerases and chimeras | |
CN112661861A (en) | Recombinant polymerase, encoding gene, preparation method, vector, kit and application | |
JP4486009B2 (en) | DNA ligase mutant | |
CN111394337A (en) | Class II V-type CRISPR protein L b2Cas12a and application thereof in gene editing | |
SIMONIC et al. | cDNA cloning and expression of the flavoprotein D-aspartate oxidase from bovine kidney cortex | |
JP2017178804A (en) | Fusion protein | |
CN116656649A (en) | IS200/IS60S transposon ISCB mutant protein and application thereof | |
EP1670932B1 (en) | Libraries of recombinant chimeric proteins | |
CN109868271A (en) | DNA is carried out using chip synthetic oligonucleotide library to shuffle the method for library de novo formation | |
US9856470B2 (en) | Process for generating a variant library of DNA sequences | |
JPH07298879A (en) | Dna polymerase gene derived from ultrathermophilic protobacterium and its use | |
CN116064462A (en) | Taq DNA polymerase mutant and preparation method thereof | |
CN114573673B (en) | Two-fork rhinoceros scarab epidermis protein, coding nucleotide sequence and application thereof | |
WO2007117331A2 (en) | Novel dna polymerase from thermoanaerobacter tengcongenesis | |
CN115261363B (en) | Method for measuring RNA deaminase activity of APOBEC3A and RNA high-activity APOBEC3A variant | |
CN116200362A (en) | Taq enzyme mutant and preparation method and application thereof | |
CN114574464B (en) | High-fidelity DNA polymerase mutant and application thereof | |
CN114317485B (en) | Recombinant murine leukemia virus reverse transcriptase mutant, preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |